Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s
Study Topline results will be released around the end of Q2 2026
BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD
Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
